Renal Transplantation in HIV-Infected Patients: The First Portuguese Review

• Type: Another Publication in an International Scientific Journal
• Date: 2015

Authors

Querido, S (Author) Other; Machado, D (Author) Other; Silva, C (Author) Other; Nolasco, F (Author) Other; Nunes, A (Author) Other; Sampaio, S (Author) FMUP; Cruz, P (Author) Other; Oliveira, C (Author) Other; Weigert, A (Author) Other

Journal

Title: Transplantation Proceedings

Vol. 47

Pages: 946-949

ISSN: 0041-1345

Publisher: Elsevier

Indexing

ISI Web of Knowledge - 1 Citation

Scopus - 1 Citation

Other information

Authenticus ID: P-00G-60Y

DOI: 10.1016/j.transproceed.2015.03.029

Abstract (EN): Introduction. With the introduction of combination antiretroviral therapy (cART), prognosis of human immunodeficiency virus (HIV) infection has been improved and kidney transplantation (KT) in HIV-positive patients became possible. Methods. We reviewed the demographic, clinical, laboratory, and therapeutic data of all the HIV-infected patients who underwent KT between 2009 (first KT in Portugal in a HIV-infected patient) and May 2014. Case accrual was through all Portuguese KT centers where a KT in an HIV-infected patient was performed. Patients were transplanted following the American and Spanish guideline recommendations that included maintenance on cART, undetectable plasma HIV RNA copies, and absolute CD4 counts of >= 200 cells/mu L in the last 6 months. Results. Fourteen KT were performed on men and 3 on women. The mean age of patients at the time of transplantation was 49.9 +/- 11.7 years. HIV status was known for 12 +/- 5 years. Eight patients had AIDS in the past and all patients received grafts from deceased donors. Twelve patients (64.7%) underwent induction therapy with basiliximab and 2 patients experienced early graft loss. In 2 patients, humoral rejection was diagnosed and in 3 patients, cellular rejection. Two patients died and an additional patient had early graft loss. Conclusion. KT is a possible, but challenging, renal replacement therapy in selected HIV-positive patients. Even in those with AIDS criteria in the past, when the disease is controlled, and after the reconstitution of the immune system with cART, KT can be performed. Nevertheless, the risk-benefit ratio for each patient needs to be taken in consideration.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 4